hh.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Potential risks of bone marrow cell transplantation into infarcted hearts
University of Bonn, Bonn, Germany.
University of Bonn, Bonn, Germany.
University of Bonn, Bonn, Germany.
University of Cologne, Cologne, Germany.
Show others and affiliations
2007 (English)In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 110, no 4, 1362-1369 p.Article in journal (Refereed) Published
Abstract [en]

Cellular replacement therapy has emerged as a novel strategy for the treatment of heart failure. The aim of our study was to determine the fate of injected mesenchymal stem cells (MSCs) and whole bone marrow (BM) cells in the infarcted heart. MSCs were purified from BM of transgenic mice and characterized using flow cytometry and in vitro differentiation assays. Myocardial infarctions were generated in mice and different cell populations including transgenic MSCs, unfractionated BM cells, or purified hematopoietic progenitors were injected. Encapsulated structures were found in the infarcted areas of a large fraction of hearts after injecting MSCs (22 of 43, 51.2%) and unfractionated BM cells (6 of 46, 13.0%). These formations contained calcifications and/or ossifications. In contrast, no pathological abnormalities were found after injection of purified hematopoietic progenitors (0 of 5, 0.0%), fibroblasts (0 of 5, 0.0%), vehicle only (0 of 30, 0.0%), or cytokine-induced mobilization of BM cells (0 of 35, 0.0%). We conclude that the developmental fate of BM-derived cells is not restricted by the surrounding tissue after myocardial infarction and that the MSC fraction underlies the extended bone formation in the infarcted myocardium. These findings seriously question the biologic basis and clinical safety of using whole BM and in particular MSCs to treat nonhematopoietic disorders.

Place, publisher, year, edition, pages
Washington, DC: American Society of Hematology , 2007. Vol. 110, no 4, 1362-1369 p.
Keyword [en]
Animals, Bone marrow transplantation, Cell differentiation, Cultured cells, Flow cytometry, Green fluorescent proteins, Mesenchymal stem cell transplantation, Mice, Inbred C57BL mice, Transgenic mice, Myocardial infarction, Risk factors, Treatment outcome
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:hh:diva-15173DOI: 10.1182/blood-2006-12-063412ISI: 000248655300045PubMedID: 17483296Scopus ID: 2-s2.0-34548044258OAI: oai:DiVA.org:hh-15173DiVA: diva2:419611
Available from: 2011-05-27 Created: 2011-05-27 Last updated: 2015-09-21Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Nygren, Jens Martin
In the same journal
Blood
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 98 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf